title: Immunohistochemical Characterization of Fumarate Hydratase (FH) and Succinate Dehydrogenase (SDH) in Cutaneous Leiomyomas for Detection of Familial Cancer Syndromes.
abstract: Hereditary leiomyomatosis and renal cell carcinoma (HLRCC) is caused by germline mutations in the FH gene, and is associated with increased incidence of leiomyomas and a potentially aggressive variant of renal cell carcinoma (HLRCC-associated RCC). Absent immunohistochemical expression of fumarate hydratase (FH) has previously been used to diagnose HLRCC-associated RCC, but immunohistochemical staining of leiomyomas is not standard practice. We performed immunohistochemistry (IHC) on whole sections from consecutive cutaneous leiomyomas from our archives to evaluate for both FH and succinate dehydrogenase B expression, in addition to clinicopathologic data collection and review of all hematoxylin and eosin-stained slides for blinded morphologic evaluation of features reported to be seen in HLRCC-associated uterine leiomyomas. Ninety-six cutaneous leiomyomas from 87 patients were identified; 12 of these specimens were from 7 patients with documented HLRCC. FH expression by IHC was absent in 9 specimens and retained in 85 specimens; 2 cases were equivocal with minimal FH expression. Seven of the 9 absent expression specimens were from patients with HLRCC, as were both of the equivocal specimens. The overall sensitivity and specificity of absent FH expression in leiomyomas for detection of patients with HLRCC were 70.0% and 97.6%, respectively. Inclusion of cases classified as equivocal increased sensitivity to 75.0%. Succinate dehydrogenase B expression was retained in 95 specimens and equivocal in 1 specimen. None of the evaluated morphologic features showed any association with leiomyomas in HLRCC. Loss of FH immunohistochemical expression in cutaneous leiomyomas is a sensitive and specific marker for detection of HLRCC, thus suggesting a role for prospective FH IHC in patients with these tumors to screen for HLRCC.
authors.affiliation: Departments of *Pathology §Dermatology †Comprehensive Cancer Center, University of Michigan Health System ‡Michigan Center for Translational Pathology, Ann Arbor, MI.
authors.forename: Cody S
authors.initials: CS
authors.lastname: Carter
authors.forename: Stephanie L
authors.initials: SL
authors.lastname: Skala
authors.forename: Arul M
authors.initials: AM
authors.lastname: Chinnaiyan
authors.forename: Jonathan B
authors.initials: JB
authors.lastname: McHugh
authors.forename: Javed
authors.initials: J
authors.lastname: Siddiqui
authors.forename: Xuhong
authors.initials: X
authors.lastname: Cao
authors.forename: Saravana M
authors.initials: SM
authors.lastname: Dhanasekaran
authors.forename: Douglas R
authors.initials: DR
authors.lastname: Fullen
authors.forename: Amir
authors.initials: A
authors.lastname: Lagstein
authors.forename: May P
authors.initials: MP
authors.lastname: Chan
authors.forename: Rohit
authors.initials: R
authors.lastname: Mehra
mesh_terms: D000293:Adolescent; D000328:Adult; D014408:Biomarkers, Tumor / Q000378:metabolism*; D016208:Databases, Factual; D005260:Female; D005649:Fumarate Hydratase / Q000378:metabolism*; D006801:Humans; D007150:Immunohistochemistry; D018231:Leiomyomatosis / Q000175:diagnosis* / Q000201:enzymology / Q000473:pathology; D008297:Male; D009386:Neoplastic Syndromes, Hereditary / Q000175:diagnosis* / Q000201:enzymology / Q000473:pathology; D012680:Sensitivity and Specificity; D016037:Single-Blind Method; D012878:Skin Neoplasms / Q000175:diagnosis* / Q000201:enzymology / Q000473:pathology; D013385:Succinate Dehydrogenase / Q000378:metabolism*; D014594:Uterine Neoplasms / Q000175:diagnosis* / Q000201:enzymology / Q000473:pathology
chemical_list: D014408:Biomarkers, Tumor; C108095:SDHB protein, human; D013385:Succinate Dehydrogenase; D005649:Fumarate Hydratase